Genetic testing to guide first treatment for large b-cell lymphoma
Part of Blood & lymphatic, Cancer clinical trials.
This study is testing whether using a special genetic test (called BostonGene Tumor Portrait™) on your biopsy sample can help doctors tailor your first chemotherapy treatment to your cancer's specific features. The goal is to see if this personalized approach leads to better outcomes with fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a confirmed diagnosis of diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (a type of blood cancer).
- Your lymphoma must be at stage 3 or 4, meaning it has spread to more than one area of the body.
- You must be able to receive the standard full dose of a chemotherapy regimen that includes drugs called anthracyclines (a common first-line treatment).
- You must have a biopsy sample that can be used for special genetic testing (called BostonGene Tumor Portrait™) to help guide treatment decisions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses special lab tests to look for tumor “molecular fingerprints” in your tumor or blood sample. The goal is to help your care team choose more personalized treatment options based on those results.
This study tests whether using a special blood test (ctDNA) to guide targeted therapy can improve outcomes for people with a type of lymphoma called DLBCL. If you qualify, you may receive a standard chemo-immunotherapy regimen (R-CHOP) possibly combined with other drugs, and your treatment plan may be adjusted based on your ctDNA levels.
This trial studies how doing genetic (DNA) testing on your cancer helps doctors choose targeted treatments, and how those treatments affect outcomes. It is for adults whose cancer has not responded to the first standard treatment or who do not have curative options.
This trial studies whether using a blood test (ctDNA) can help guide treatment decisions for people with newly diagnosed diffuse large B-cell lymphoma. It tests standard chemotherapy regimens (R-CHOP or R-pola-CHP) and aims to improve outcomes by monitoring tumor DNA in the blood.
This study checks whether a blood test can find tumor genetic changes (called “plasma genomic profiling”) to help choose the best next treatment. It may help your care team decide therapy after your cancer progresses or seems likely to progress soon.
This trial uses a genetic test on your lymphoma tissue to help choose your treatment. It may help personalize therapy for people with newly diagnosed peripheral T-cell lymphoma and see how well the approach works and is tolerated.
Hear when a new LBCL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.